Arecor Therapeutics PLC Appointment of SVP for Tetris Pharma Ltd (4316Y)
03 January 2024 - 6:00PM
UK Regulatory
TIDMAREC
RNS Number : 4316Y
Arecor Therapeutics PLC
03 January 2024
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR APPOINTS DR HELEN PARRIS AS SENIOR VICE PRESIDENT,
COMMERCIAL AND GENERAL MANAGER OF TETRIS PHARMA LTD
Cambridge, UK, 3 January 2024: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical company advancing today's therapies to
enable healthier lives, is pleased to announce the appointment of
Dr. Helen Parris as Senior Vice President, Commercial and General
Manager of the Group's subsidiary company, Tetris Pharma Ltd
("Tetris Pharma"), effective Monday 15 January 2024.
Helen has over 20 years of scientific, commercial and government
affairs experience across several international biopharmaceutical
companies and has been responsible for launching transformational
products and shaping markets across large pharmaceutical and
biotechnology companies. Prior to joining Tetris Pharma, Helen
served as General Manager Northern Markets (UK, Netherlands and
Nordics) at Albireo Pharma, Inc., which was acquired by Ipsen
(Euronext: IPN; ADR: IPSEY) in March 2023, and where she played a
key role in establishing and building the regional affiliate and
launching the first product to market.
Previously, Helen held multiple positions at Gilead (NASDAQ:
GILD), including Executive Director EMEA, Global Affairs Regional
Lead, and was instrumental in broadening patient access to
treatment. Whilst at Gilead, Helen led the launch of several
transformational drugs, developed critical launch strategies and
expanded commercial opportunities.
Helen holds a BSc in Biology from York University, a PhD from
Leeds University and an MBA from Henley Management College.
Sarah Howell, Chief Executive Officer at Arecor, said: "I am
delighted to welcome Helen to Tetris Pharma and the Arecor Group as
a key member of our leadership team. Helen's proven track record in
bringing products to market and growing sales will be key as we
continue the roll-out of Ogluo(R) across the UK and Europe. Ogluo
(R) is an important treatment for people with diabetes and their
caregivers that can provide them with the confidence to manage
severe hypoglycaemic events and, under Helen's leadership, Tetris
Pharma is even better positioned for the continued adoption of this
key product in a c.GBP100 million market. Not only will this
deliver a revenue stream but a successful commercial distribution
platform through Tetris Pharma is highly complementary to our
existing specialty hospital products business and has significant
growth potential, providing Arecor with the capability to take
selected products to market in the UK and Europe."
Dr. Helen Parris, S enior Vice President, Commercial and General
Manager at Tetris Pharma, commented: "I am thrilled to be joining
the team at Tetris Pharma to support the development of the
company's lead product, Ogluo (R), and continue its accelerated
roll-out across Europe. Ogluo(R) meets a key need for people living
with diabetes at risk of severe hypoglycaemia, a condition which
can have a profound effect on the everyday lives of those with
diabetes and their caregivers. I look forward to leading the
company as it continues to expand its pan-European presence."
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
ICR Consilium
Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700
Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary technology platform,
Arestat(TM), we are developing an internal portfolio of proprietary
products in diabetes and other indications, as well as working with
leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat(TM) platform is supported by an
extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAXFAEALLEFA
(END) Dow Jones Newswires
January 03, 2024 02:00 ET (07:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2024 to May 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From May 2023 to May 2024